Health Trials

About this trial

Schizophrenia and depression are among the most disabling disorders in all of medicine. Cognitive deficits play a key role in patients' disability, affecting their capacity to contribute actively to society by sustaining employment or academic activity. Moreover, cognitive difficulties tend to persist even after the stabilization of other clinical symptoms. Verbal memory and emotion regulation are two important cognitive domains that are impaired in schizophrenia and depression and are associated with patients' functional outcomes. In this study, brain imaging is used to investigate the brain mechanisms underlying these cognitive deficits in these populations.

Eligibility criteria

Qualifiers

age 18-60 years

current Intelligence Quotient (IQ) > 70 as measured by the Wechsler Abbreviated Scale of Intelligence (WASI)

the ability to read and speak fluent English

a diagnosis of schizophrenia, schizoaffective or major depression disorder

Disqualifiers

significant neurological or other medical disorders that may produce cognitive impairment

a recent history of substance abuse or dependence (within the past 3 months)

any magnetic resonance imaging (MRI) contraindications (e.g. metallic head implant, history of seizure, pacemaker)

decisional incapacity requiring a guardian

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

90 Participants
are grouped into 3 trial groups

Locations

1
Royal Ottawa Mental Health CenterK1Z 7K4, OttawaOntario, Canada

Sponsors and collaborators

The Royal Ottawa Mental Health Centre

Lead sponsor

Source ClinicalTrials.gov